Eli Lilly’s Retatrutide Yields 28% Weight Loss at 80 Weeks and 30% at 104 Weeks
LLY•Eli Lilly’s Phase III retatrutide trial showed a clear dose-response, with the 12mg dose delivering 28% weight loss at 80 weeks in BMI≥30 patients and 30% at 104 weeks in a BMI≥35 extension cohort. At 12mg, nausea occurred in 42%, diarrhea in 32%, vomiting in 25% and discontinuation was 11%.
1. Phase III Efficacy Results
Phase III data demonstrated a clear dose-response from 4mg to 12mg, with the 12mg dose delivering roughly 28% weight loss at 80 weeks in BMI≥30 patients and 30% at 104 weeks in a BMI≥35 extension cohort. Lower-dose cohorts showed around 19% weight loss after one escalation step.
2. Safety and Tolerability
At the 12mg dose, nausea was reported in 42% of participants, diarrhea in 32% and vomiting in 25%, while discontinuation rates reached 11% versus 5% for placebo. These tolerability outcomes align with expectations for GLP-1 therapies and are comparable to those seen with existing obesity treatments.
3. Market Positioning and Differentiation
Eli Lilly appears to position retatrutide primarily for patients with BMI over 35, aiming to sustain differentiation against expected generic competition that may offer up to 15% weight loss. Analysts view the combination of strong efficacy and tolerability as supporting a differentiated post-generic obesity treatment.
4. Upcoming ADA Presentation
Further details will be disclosed at the upcoming ADA meeting, with a focus on additional safety and tolerability metrics, including heart rate effects. Earlier Phase II data indicated a heart rate increase of about 6–7 beats per minute for the drug’s mechanism versus roughly 2–3 BPM for tirzepatide.
